[
    [
        {
            "time": "",
            "original_text": "智飞生物2020年一季度净利逆势增长 今日盘中股价创历史新高",
            "features": {
                "keywords": [
                    "智飞生物",
                    "2020年一季度",
                    "净利",
                    "逆势增长",
                    "股价",
                    "历史新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物2020年一季度净利逆势增长 今日盘中股价创历史新高",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【民生医药|点评】智飞生物：受新冠疫情影响业绩增速暂时放缓, EC和预防性微卡有望很快获批",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新冠疫情",
                    "业绩增速",
                    "放缓",
                    "EC",
                    "预防性微卡",
                    "获批"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【民生医药|点评】智飞生物：受新冠疫情影响业绩增速暂时放缓, EC和预防性微卡有望很快获批",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【智飞生物 | Q1预告点评】疫情期间维持正增长，预防用微卡有望近期获批",
            "features": {
                "keywords": [
                    "智飞生物",
                    "Q1预告",
                    "疫情期间",
                    "正增长",
                    "预防用微卡",
                    "获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【智飞生物 | Q1预告点评】疫情期间维持正增长，预防用微卡有望近期获批",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "A股首只创新药ETF今日上市，这一指数年化收益超16%",
            "features": {
                "keywords": [
                    "A股",
                    "创新药ETF",
                    "上市",
                    "指数",
                    "年化收益",
                    "16%"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "ETF"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "A股首只创新药ETF今日上市，这一指数年化收益超16%",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "渝股看台｜“重庆第一高价股”智飞生物一季度净利预增10%",
            "features": {
                "keywords": [
                    "渝股",
                    "智飞生物",
                    "一季度",
                    "净利",
                    "预增",
                    "10%"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "渝股看台｜“重庆第一高价股”智飞生物一季度净利预增10%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]